$PMDI
PSYCHEMEDICS CORP Stock $pmdi

$pmdi Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000117184322003580 Filed on May 11, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$6.508M	$5.713M
YoY Change	13.92%	-24.2%
Cost Of Revenue	$4.067M	$3.145M
YoY Change	29.32%	-34.6%
Gross Profit	$2.441M	$2.568M
YoY Change	-4.95%	-5.87%
Gross Profit Margin	37.51%	44.95%
Selling, General & Admin	$2.133M	$2.171M
YoY Change	-1.75%	-17.73%
% of Gross Profit	87.38%	84.54%
Research & Development	$318.0K	$280.0K
YoY Change	13.57%	-15.41%
% of Gross Profit	13.03%	10.9%
Depreciation & Amortization	$628.0K	$690.0K
YoY Change	-8.99%	13.11%
% of Gross Profit	25.73%	26.87%
Operating Expenses	$2.451M	$2.451M
YoY Change	0.0%	-17.47%
Operating Profit	-$10.00K	$117.0K
YoY Change	-108.55%	-148.35%
Interest Expense	-$9.000K	-$10.00K
YoY Change	-10.0%	-85.71%
% of Operating Profit		-8.55%
Other Income/Expense, Net	$66.00K	-$14.00K
YoY Change	-571.43%	-80.82%
Pretax Income	$56.00K	$103.0K
YoY Change	-45.63%	-132.7%
Income Tax	$17.00K	$20.00K
% Of Pretax Income	30.36%	19.42%
Net Earnings	$39.00K	$83.00K
YoY Change	-53.01%	-152.2%
Net Earnings / Revenue	0.6%	1.45%
Basic Earnings Per Share	$0.01	$0.01
Diluted Earnings Per Share	$0.01	$0.01
COMMON SHARES
Basic Shares Outstanding	5.590M	5.537M
Diluted Shares Outstanding	5.646M	5.644M

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.127M	$2.190M
YoY Change	-2.88%	-58.91%
Cash & Equivalents	$2.100M	$2.190M
Short-Term Investments
Other Short-Term Assets	$1.033M	$1.900M
YoY Change	-45.63%	0.53%
Inventory
Prepaid Expenses
Receivables	$4.704M	$4.020M
Other Receivables	$2.661M	$2.520M
Total Short-Term Assets	$10.53M	$10.63M
YoY Change	-0.96%	-1.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.441M	$8.616M
YoY Change	9.58%	-20.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$842.0K	$882.0K
YoY Change	-4.54%	-5.77%
Total Long-Term Assets	$10.44M	$13.75M
YoY Change	-24.07%	-4.7%
TOTAL ASSETS
Total Short-Term Assets	$10.53M	$10.63M
Total Long-Term Assets	$10.44M	$13.75M
Total Assets	$20.97M	$24.38M
YoY Change	-14.0%	-3.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$722.0K	$1.109M
YoY Change	-34.9%	-10.13%
Accrued Expenses	$3.045M	$1.567M
YoY Change	94.32%	-25.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$563.0K	$691.0K
YoY Change	-18.52%	1.62%
Total Short-Term Liabilities	$5.324M	$4.330M
YoY Change	22.96%	-11.87%
LONG-TERM LIABILITIES
Long-Term Debt	$526.0K	$3.270M
YoY Change	-83.91%	83.71%
Other Long-Term Liabilities	$2.657M	$3.760M
YoY Change	-29.34%	70.14%
Total Long-Term Liabilities	$526.0K	$3.270M
YoY Change	-83.91%	83.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.324M	$4.330M
Total Long-Term Liabilities	$526.0K	$3.270M
Total Liabilities	$8.507M	$11.57M
YoY Change	-26.46%	23.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.511M	-$8.523M
YoY Change	11.59%	73.73%
Common Stock	$33.69M	$33.05M
YoY Change	1.93%	1.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$10.08M	$10.08M
YoY Change	0.0%	0.0%
Treasury Stock Shares	$668.0K	$668.0K
Shareholders Equity	$12.46M	$12.81M
YoY Change
Total Liabilities & Shareholders Equity	$20.97M	$24.38M
YoY Change	-14.0%	-3.29%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	$39.00K	$83.00K
YoY Change	-53.01%	-152.2%
Depreciation, Depletion And Amortization	$628.0K	$690.0K
YoY Change	-8.99%	13.11%
Cash From Operating Activities	$345.0K	-$413.0K
YoY Change	-183.54%	0.0%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$7.000K
YoY Change	42.86%	-98.25%
Acquisitions
YoY Change
Other Investing Activities	$7.000K	-$10.00K
YoY Change	-170.0%	-242.86%
Cash From Investing Activities	-$36.00K	-$59.00K
YoY Change	-38.98%	-82.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$174.0K	-$171.0K
YoY Change	1.75%	-85.28%
NET CHANGE
Cash From Operating Activities	$345.0K	-$413.0K
Cash From Investing Activities	-$36.00K	-$59.00K
Cash From Financing Activities	-$174.0K	-$171.0K
Net Change In Cash	$135.0K	-$643.0K
YoY Change	-121.0%	-67.06%
FREE CASH FLOW
Cash From Operating Activities	$345.0K	-$413.0K
Capital Expenditures	$10.00K	$7.000K
Free Cash Flow	$335.0K	-$420.0K
YoY Change	-179.76%	-48.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5591656
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	108000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	89000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20272000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19659000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	873000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	873000
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6259000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6257000
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5590000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5589000
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	668000
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	668000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	83000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2127000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1992000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4704000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4116000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1033000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1499000	USD
CY2022Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2661000	USD
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2678000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	10525000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10285000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6121000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6691000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	842000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	864000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	160000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	160000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3320000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3552000	USD
CY2022Q1	us-gaap	Assets Assets	20968000	USD
CY2021Q4	us-gaap	Assets Assets	21552000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	722000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	994000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3045000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3188000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	563000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	664000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	994000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	984000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5324000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5830000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	526000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	599000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2657000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2880000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	8507000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	9309000	USD
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	33657000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	33478000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9511000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9550000	USD
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	10082000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	10082000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1634000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1634000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	12461000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12243000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20968000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21552000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6508000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5713000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4067000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3145000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	2441000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	2568000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1327000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1529000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	806000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	642000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	318000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	280000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2451000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	2451000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	117000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	66000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	56000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	103000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	39000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	83000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12243000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	179000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	39000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	12461000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	12512000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	217000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	83000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	12812000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	39000	USD
CY2022Q1	pmd	Depreciation And Amortization Excluding Rou Asset Amortization DepreciationAndAmortizationExcludingRouAssetAmortization	628000	USD
CY2021Q1	pmd	Depreciation And Amortization Excluding Rou Asset Amortization DepreciationAndAmortizationExcludingRouAssetAmortization	687000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	232000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	224000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	179000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	217000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	588000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	664000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-466000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	984000	USD
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-17000	USD
CY2021Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	24000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-272000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	525000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-213000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-243000	USD
CY2022Q1	pmd	Increase Decrease In Accrued Expenses And Accrued Income Taxes IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes	-143000	USD
CY2021Q1	pmd	Increase Decrease In Accrued Expenses And Accrued Income Taxes IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes	-234000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	345000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-413000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
CY2022Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	33000	USD
CY2021Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	43000	USD
CY2022Q1	pmd	Payments For Proceeds From Other Assets PaymentsForProceedsFromOtherAssets	-7000	USD
CY2021Q1	pmd	Payments For Proceeds From Other Assets PaymentsForProceedsFromOtherAssets	9000	USD
CY2021Q1	pmd	Payments Of Equipment Financing PaymentsOfEquipmentFinancing	171000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59000	USD
CY2022Q1	pmd	Payments Of Equipment Financing PaymentsOfEquipmentFinancing	174000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-174000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-171000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	135000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-643000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1992000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2833000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2127000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2190000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	10000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	14000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	269000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	269000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	193000	USD
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	7000	USD
CY2022Q1	pmd	Income Tax Benefit Cares Act IncomeTaxBenefitCARESAct	0	USD
CY2021Q1	pmd	Income Tax Benefit Cares Act IncomeTaxBenefitCARESAct	800000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2100000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	179000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	217000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	574000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.23
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	-0
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	574000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.23
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	93000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	473000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.90
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	28000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5590000
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5537000
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	56000
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	107000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5646000
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5644000
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	56000
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	107000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3700000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.039	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	269000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	822000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1118000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1034000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	544000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	460000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3978000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	327000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3651000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	994000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2657000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3651000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6508000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5713000	USD

Files In Submission

Name	View Source	Status
0001171843-22-003580-index-headers.html	Edgar Link	pending
0001171843-22-003580-index.html	Edgar Link	pending
0001171843-22-003580.txt	Edgar Link	pending
0001171843-22-003580-xbrl.zip	Edgar Link	pending
ex_371492.htm	Edgar Link	pending
ex_371493.htm	Edgar Link	pending
ex_371494.htm	Edgar Link	pending
ex_371495.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pmd-20220331.xsd	Edgar Link	pending
pmd-20220331_cal.xml	Edgar Link	unprocessable
pmd-20220331_def.xml	Edgar Link	unprocessable
pmd-20220331_lab.xml	Edgar Link	unprocessable
pmd-20220331_pre.xml	Edgar Link	unprocessable
pmd20220331_10q.htm	Edgar Link	pending
pmd20220331_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PMDI
PSYCHEMEDICS CORP Stock $pmdi

2022 Q1 Form 10-Q Financial Statement

#000117184322003580 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMDI PSYCHEMEDICS CORP Stock $pmdi

2022 Q1 Form 10-Q Financial Statement

#000117184322003580 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMDI
PSYCHEMEDICS CORP Stock $pmdi